button bars forest bayes pooled summary circles
 
deaths (OS)

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)

versus placebo
pembrolizumab alone vs. placebo 1 1.0better0.35.098 %

metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)

versus sunitinib
atezolizumab alone vs. sunitinib 1 -
atezolizumab plus bevacizumab vs. sunitinib 2 1.0better0.35.076 %
avelumab plus axitinib vs. sunitinib 1 1.0better0.35.096 %
nivolumab plus cabozantinib vs. sunitinib 1 1.0better0.35.099 %
nivolumab plus ipilimumab vs. sunitinib 3 1.0better0.35.099 %
pembrolizumab plus axitinib vs. sunitinib 1 1.0better0.35.0100 %
pembrolizumab plus lenvatinib vs. sunitinib 1 1.0better0.35.0100 %

mRCC - L1 - PDL1 negative metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 negative

versus sunitinib
atezolizumab plus bevacizumab vs. sunitinib 1 -

mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive

versus sunitinib
atezolizumab alone vs. sunitinib 1 -
atezolizumab plus bevacizumab vs. sunitinib 2 1.0better0.35.087 %
avelumab plus axitinib vs. sunitinib 1 1.0better0.35.0100 %

metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)

versus everolimus
nivolumab alone vs. everolimus 1 1.0better0.35.099 %

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons